Equities

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)26.40
  • Today's Change-7.39 / -21.87%
  • Shares traded2.68m
  • 1 Year change-11.88%
  • Beta1.4200
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd, formerly Tianjin Zhongxin Pharmaceutical Group Co Ltd, is a China-based company mainly engaged in the production, operation and scientific research of green traditional Chinese medicine. The Company's businesses cover the whole industry chain of traditional Chinese medicine, including the cultivation of Chinese medicinal materials, trade of Chinese medicinal materials, research and development (R&D), production and sales of Chinese patent medicines, production and sales of Chinese herbal decoction pieces, pharmaceutical commercial logistics, pharmaceutical retailing, chemical raw materials and preparations, biomedicine and many other fields. The Company's products include cardiovascular and cerebrovascular medicines, respiratory medicines, spleen and stomach medicines, cold medicines, oncology medicines, gynecological medicines, pediatric medicines and other other product groups.

  • Revenue in CNY (TTM)8.04bn
  • Net income in CNY932.37m
  • Incorporated1981
  • Employees4.62k
  • Location
    Tianjin Pharmaceutical Da Ren Tang Group Corp LtdNo. 17, Baidi Road, Nankai DistrictTIANJIN 300193ChinaCHN
  • Phone+86 2 227020892
  • Fax+86 2 227020892
  • Websitehttps://www.jydrt.com.cn/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Tonghua Dongbao Pharmaceutical Co Ltd2.43bn341.31m17.72bn3.20k57.762.76--7.290.15480.15481.253.240.33940.74263.70760,839.104.7618.685.0419.6877.3178.7314.0339.202.60--0.071241.7310.692.69-26.176.85-14.754.56
Liaoning Cheng Da Co Ltd11.29bn346.30m18.37bn3.36k52.960.6218--1.630.22680.22687.4219.310.23715.285.773,365,262.000.23223.590.32975.2113.9014.150.97939.890.9129--0.283115.93-25.97-10.97-80.95-21.267.04--
Shandong Buchang Pharmaceuticals Co Ltd11.78bn-293.31m19.20bn8.31k--1.72--1.63-0.2619-0.261910.7610.090.57771.089.781,416,955.00-2.263.26-3.134.7258.2574.71-3.924.850.50700.16020.2675121.01-11.41-0.6219120.85-29.93-16.56-36.72
Joincare Pharmaceutical Group Ind. Co.15.89bn1.47bn22.21bn14.37k14.801.53--1.400.80060.80068.657.730.44192.275.661,106,434.008.458.4617.5818.8461.9662.7219.1317.001.94--0.224128.86-2.908.24-3.9915.5811.532.38
Tianjin Pharmcetl Da Ren Tang Grp Cp Ltd8.04bn932.37m22.56bn4.62k28.014.05--2.811.211.2110.428.340.75672.643.241,740,681.008.668.9613.5512.8045.8040.8211.4410.671.31--0.204756.93-0.32665.2814.4911.93-4.3342.22
China Resources Dubl-Crne Phrmctl Co Ltd11.22bn1.65bn22.57bn12.27k13.522.21--2.011.611.6110.939.810.71063.046.08914,865.0010.548.4014.7011.0856.3458.1914.8311.981.26--0.063335.916.204.4412.966.6021.46-1.63
Tasly Pharmaceutical Group Co Ltd8.57bn880.84m22.83bn9.22k26.001.80--2.670.58780.58785.738.510.49641.738.48928,676.304.895.476.147.2565.2848.429.868.942.193.890.176650.990.4236-13.57505.34-7.07-3.031.92
Nanjing King-Frind Bchmcl Phrmctcl C Ltd3.88bn-422.97m24.15bn1.45k--3.85--6.23-0.3269-0.32692.433.880.37740.50124.352,672,280.00-4.128.97-5.7613.1541.0045.59-10.9120.121.51-2.960.26926.335.8918.25-117.37--38.3213.75
Shanghai Junshi Biosciences Co Ltd1.79bn-1.80bn26.17bn2.53k--4.88--14.64-1.83-1.831.816.260.15930.84064.29695,986.10-17.55-18.87-21.98-23.1169.0769.13-110.18-88.411.75-67.730.3065--3.38248.394.38--8.36--
Data as of Sep 13 2024. Currency figures normalised to Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

5.19%Per cent of shares held by top holders
HolderShares% Held
Zhong Ou Asset Management Co., Ltdas of 30 Sep 202313.84m2.43%
China Southern Asset Management Co., Ltd.as of 30 Jun 20243.57m0.63%
GF Fund Management Co., Ltd.as of 30 Jun 20243.21m0.56%
First Seafront Fund Management Co., Ltd.as of 30 Jun 20242.55m0.45%
China Universal Asset Management Co., Ltd.as of 30 Jun 20242.03m0.36%
The Vanguard Group, Inc.as of 30 Sep 20241.59m0.28%
Value Partners Ltd.as of 30 Jun 2023728.41k0.13%
Lion Fund Management Co., Ltd.as of 30 Jun 2024726.71k0.13%
China Asset Management Co., Ltd.as of 30 Jun 2024686.14k0.12%
Fullgoal Fund Management Co., Ltd.as of 30 Jun 2024664.40k0.12%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.